
Rhythm Pharmaceuticals, Inc.: updates and filings
Price
$119.04
November 18, 2026Market cap $8.1B
What Ploutos Investor adds for Rhythm Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 38% since Nov 3, 2026, when the 10-Q these figures come from was filed ($86.44 then, $119.04 on Nov 18, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 3, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 3, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 3, 2026Results of operationsForm8-K
- Oct 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 4, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Jun 25, 2026Shareholder voteForm8-K
- Jun 15, 2026Regulation FD disclosure, other material eventsForm8-K
- May 29, 2026Additional annual meeting materialFormDEFA14A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 5, 2026Shares registered for employeesFormS-8
- May 5, 2026Additional annual meeting materialFormDEFA14A
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Results of operationsForm8-K
- Apr 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Apr 3, 2026Officer or director change, Regulation FD disclosureForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 26, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 20, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 16, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 2, 2026Regulation FD disclosure, other material eventsForm8-K
- Feb 26, 2026Shelf registration for future offeringsFormS-3ASR
- Feb 26, 2026Shares registered for employeesFormS-8
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 3, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 3, 2026 | 8-K | Results of operations | Document |
| Oct 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 4, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Jun 25, 2026 | 8-K | Shareholder vote | Document |
| Jun 15, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 5, 2026 | S-8 | Shares registered for employees | Document |
| May 5, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 3, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 20, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 16, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 2, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Feb 26, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Feb 26, 2026 | S-8 | Shares registered for employees | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 12, 2015.
The full analysis
What do Rhythm Pharmaceuticals's filings show?
The filings are where every one of Rhythm Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.